Saturday, September 24, 2016 2:30:19 PM
Achillion partners with J&J to develop hepatitis C drugs
Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.
Achillion will be eligible for milestone payments of up to $1.1 billion related to the development, regulatory approval and sales of the drugs.
Johnson & Johnson will also invest $225 million in Achillion in return for about 18.4 million unregistered shares at $12.25 per share.
Achillion is developing three hepatitis C drugs -- ACH-3102 and sovaprevir in mid-stage trials and ACH-3422 in early-stage trials.
ACH-3102, which was granted fast-track designation in the United States, will be part of the oral regimen that could shorten treatment time to six weeks by 2018, the companies said on a call with analysts.
Gilead Sciences Inc's recently approved pill Harvoni requires at least eight weeks of treatment. The pill combines two of Gilead's other drugs - ledipasvir and sovaldi.
The fight against hepatitis C has made huge gains in recent years. A couple of years ago, patients needed 48 weeks of treatment with drugs that had harsh side effects. They cured only about 40 percent of patients.
The new all-oral treatments seek to replace injectable interferon and its flu-like side effects as well as an older drug called ribavirin that caused anemia and other problems.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM